Nifty outlook and few trading ideas by Vaishali Parekh, Research Analyst - Technical Research at Prabhudas Lilladher
Nifty outlook and top trading ideas by Vinay Rajani - Technical Analyst, HDFC Securities
Nifty, Bank Nifty, Maruti Suzuki, Sun Pharma and Vedanta
The company dominates with a 60% or more market share
The regulator said it has decided to enhance the overseas investment limit of AIFs and VCFs to $750 million
Axis Bank topped the league table, with Citibank coming a close second
Its operating profit is expected to improve 24% annually over FY18-21
Prospects across segments stay positive
Global financial services firm had entered into a pact with RIL in 2011
Among sectoral indices, the Nifty Pharma index settled 2.1% higher led by a rise in shares of Aurobindo Pharma and Cipla.
At 02:43 pm; Nifty Pharma index, the largest gainer among sectoral indices, was up 2.3% as compared to 0.46% rise in the Nifty 50 index.
Nomura has kept the December 2018 target for the S&P BSE Sensex unchanged at 11,380 levels from their earlier forecast.
Graphite India hit a new high of Rs 925, up 5%, while HEG too up 5% to Rs 3,650, trading close to its record high of Rs 3,695 touched on May 17, 2018 on the BSE in intra-day trade.
Promoters of these delisted companies will be required to purchase the shares from the public shareholders
The stock is up 20% at Rs 576 after the Singapore court dismissed all the claims and counterclaims against promoters Pravin Kiri, Manish Kiri and others.
ICICI Securities (Rs 316) and ICICI Pru Life (Rs 361) were down 3% each in intra-day trade on the BSE.
Regulator finds fund house violated MF code of conduct
Nifty outlook and few trading ideas by Vaishali Parekh, Research Analyst - Technical Research at Prabhudas Lilladher
Nifty outlook and top trading ideas by Jay Anand Thakkar, CMT -Assistant Vice President - Equity Research, Anand Rathi Research
Prices up by 8% in June and another hike is in the offing